Vontobel Rebalances Portfolio with Major Medtronic Stake Increase and BMY, FSLR Trims

Key Facts

1Vontobel Holding Ltd. sold 248,546 shares of Bristol Myers Squibb during the fourth quarter.

2Vontobel increased its stake in Medtronic by 111.7%, purchasing 520,768 additional shares.

3Vontobel reduced its position in First Solar by 9.5%, selling 31,264 shares.

In a move reflecting a selective strategy within the healthcare and renewable energy sectors, Vontobel Holding Ltd. disclosed significant adjustments to its investment portfolio. The institution increased its stake in Medtronic by 111.7% by purchasing 520,768 additional shares, while simultaneously opting for partial liquidation in other positions. This included selling 248,546 shares of Bristol Myers Squibb and reducing its position in First Solar by 9.5% through the sale of 31,264 shares.

These adjustments come at a time when all three companies exceeded analyst expectations in their recent financial results, suggesting a tactical profit recycling by the Swiss institution. Compared to peers, Medtronic trades at attractive valuation levels relative to its rival Boston Scientific, which has seen robust revenue growth recently per market data. The partial exit from First Solar reflects a cautious stance toward the solar sector, which faces headwinds from high interest rates despite the company beating quarterly earnings estimates by a wide margin according to recent earnings reports.

Looking at current price levels, MDT stood at $80.20, while BMY closed at $57.13 and FSLR at $267.31 (close June 12, 2026). Investors should monitor any commentary from Federal Reserve officials, such as the recent speech by Fed Barr noted in the economic calendar, as the sensitivity of growth stocks in the biotech and renewable sectors remains high regarding monetary policy outlooks.